Stock Events

Stock Events

Search...

XOMA Royalty

€28.8

50

+€2+7.46% Wednesday 08:59

Statistics

Day High

28.8

Day Low

28.8

52W High

-

52W Low

-

Volume

0

Avg. Volume

-

Mkt Cap

281.22M

P/E Ratio

-

Dividend Yield

-

Dividend

-

Upcoming

Earnings

5NovExpected

Q1 2023

Q2 2023

Q3 2023

Q4 2023

Q1 2024

Q2 2024

Next

-1.87

-0.97

-0.06

0.84

Expected EPS

-0.436667

Actual EPS

N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow X0M1.F. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals competes in the biotechnology industry focusing on developing and commercializing medicines for serious medical conditions, similar to XOMA's focus on antibody-based therapeutics.

Amgen is a biopharmaceutical company that discovers, develops, manufactures, and delivers innovative human therapeutics, competing directly with XOMA in the biotech sector.

Biogen competes with XOMA in the biotechnology field, focusing on developing therapies for neurological and neurodegenerative diseases.

Gilead Sciences

Gilead Sciences is a biopharmaceutical company that researches, develops, and commercializes drugs in areas similar to XOMA, making them direct competitors.

Vertex Pharmaceuticals

Vertex Pharmaceuticals is involved in creating new possibilities in medicine to cure diseases and improve people's lives, competing with XOMA in the biotech innovation space.

Alnylam Pharmaceuticals

Alnylam Pharmaceuticals is a leader in RNAi therapeutics, competing with XOMA in the development of novel therapeutics.

Incyte Corporation focuses on the discovery, development, and commercialization of proprietary therapeutics, making it a competitor in the biopharmaceutical space alongside XOMA.

Nektar Therapeutics

Nektar Therapeutics is involved in developing new treatment options in various therapeutic areas, competing with XOMA in the innovation of biologic drugs.

Biomarin Pharmaceutical

BioMarin Pharmaceutical focuses on developing and commercializing innovative biopharmaceuticals for rare diseases, competing with XOMA in targeting niche markets with specialized treatments.

About

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets. It has a portfolio with various assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.

Show more...

CEO

Mr. Owen P. Hughes Jr.

Employees

13

Country

US

ISIN

US98419J2069

WKN

000A2ATUH

Listings